

Jeptha F. Barbour
Florida Bar No.: 0347000
Edward L. Birk
Florida Bar No.: 068462
MARKS GRAY, P.A.
Post Office Box 447
Jacksonville, FL 32201
(904) 398-0900

OF COUNSEL:

Bruce M. Wexler
Joseph M. O'Malley, Jr.
Eric W. Dittmann
Isaac S. Ashkenazi
Leonard A. Monfredo
PAUL HASTINGS LLP
75 East 55th Street
New York, NY 10022
(212) 318-6000

Attorneys for Plaintiffs

*Boehringer Ingelheim Pharma GmbH & Co. KG,
Boehringer Ingelheim International GmbH, and
Boehringer Ingelheim Pharmaceuticals, Inc.*

**UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF FLORIDA
WEST PALM BEACH DIVISION**

BOEHRINGER INGELHEIM PHARMA GMBH
& CO. KG, BOEHRINGER INGELHEIM
INTERNATIONAL GMBH, and BOEHRINGER
INGELHEIM PHARMACEUTICALS, INC.,

Plaintiffs,

v.

BRECKENRIDGE PHARMACEUTICAL, INC.,

Defendant.

Civil Action No. _____

**COMPLAINT FOR
PATENT INFRINGEMENT**

(Filed Electronically)

Plaintiffs *Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim International GmbH, and Boehringer Ingelheim Pharmaceuticals, Inc.* (collectively,

“Boehringer” or “Plaintiffs”), by their undersigned attorneys, for their Complaint against Defendant Breckenridge Pharmaceutical, Inc. (“Breckenridge”) hereby allege as follows:

THE PARTIES

1. Plaintiff Boehringer Ingelheim Pharma GmbH & Co. KG (“BIPKG”) is a limited partnership organized and existing under the laws of Germany, having a principal place of business at Binger Strasse 173, 55216 Ingelheim, Germany.

2. Plaintiff Boehringer Ingelheim International GmbH (“BII”) is a private limited liability company organized and existing under the laws of Germany, having a principal place of business at Binger Strasse 173, 55216 Ingelheim, Germany.

3. Plaintiff Boehringer Ingelheim Pharmaceuticals, Inc. (“BIPI”) is a corporation organized and existing under the laws of the state of Delaware, having a principal place of business at 900 Ridgebury Road, Ridgefield, Connecticut 06877.

4. Defendant Breckenridge is a corporation organized and existing under the laws of the state of Florida, having a principal place of business at 6111 Broken Sound Parkway, NW, Suite 170, Boca Raton, Palm Beach County, Florida 33487.

NATURE OF THE ACTION

5. This is a civil action concerning United States Patent No. 6,087,380 (“the ‘380 patent”). This action arises under the Patent Laws of the United States, 35 U.S.C. § 100, *et seq.* and the Declaratory Judgment Act, 28 U.S.C. §§ 2201-02.

JURISDICTION AND VENUE

6. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

7. Venue is proper in this Court under 28 U.S.C. §§ 1391(c) and 1400(b).

8. Defendant Breckenridge develops, manufactures, and/or distributes generic drugs for sale and use throughout the United States, including in this Judicial District.

9. This Court has personal jurisdiction over Breckenridge because, *inter alia*, it is a corporation organized and existing under the laws of the State of Florida, and because it maintains its principal place of business in the State of Florida.

10. This Court has personal jurisdiction over Breckenridge because, *inter alia*, Breckenridge: (1) has substantial, continuous, and systematic contacts with this State; (2) intends to market, sell, and/or distribute Breckenridge's infringing Abbreviated New Drug Application ("ANDA") products ("Breckenridge's ANDA products," as defined in paragraph 15 *infra*) to residents of this State; (3) maintains a broad distributorship network within this State; and (4) enjoys substantial income from sales of its generic pharmaceutical products in this State.

11. Additionally, Breckenridge has previously consented to this Court's jurisdiction and availed itself of the protections afforded by this Judicial District. *See, e.g., Nestle Health Science Pamlab Inc. et al. v. Virtus Pharm., LLC*, No. 14-22515-KMW (S.D. Fla. Jul. 8, 2014); *Pamlab, L.L.C. et al. v. Virtus Pharm., LLC*, No. 12-81202-KMW (S.D. Fla. Oct. 29, 2012); and *Breckenridge Pharm., Inc. v. Sonar Prods., Inc.*, No. 10-80705-KAM (S.D. Fla. Jun. 11, 2010).

PATENT-IN-SUIT

12. BIPI is the holder of New Drug Application ("NDA") No. 22-512, by which the United States Food and Drug Administration ("FDA") first granted approval for 75 mg and 150 mg dabigatran etexilate mesylate capsules. The dabigatran etexilate mesylate capsules described in BIPI's NDA are prescribed, *inter alia*, to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Boehringer sells these capsules in the

United States under the trade name “PRADAXA[®].”

13. BIPKG owns the '380 patent, which was duly and legally issued on July 11, 2000, and is titled “Disubstituted Bicyclic Heterocycles, the Preparations and the Use Thereof as Pharmaceutical Compositions.” BII and BIPI have an exclusive license under the '380 patent in the United States from BIPKG. A copy of the '380 patent is attached as Exhibit A.

ACTS GIVING RISE TO THIS ACTION

COUNT I – INFRINGEMENT OF THE '380 PATENT BY BRECKENRIDGE

14. Plaintiffs reallege paragraphs 1-13 as if fully set forth herein.

15. Defendant Breckenridge filed with the FDA ANDA No. 207922, which included a certification with respect to the '380 patent under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j)(2)(A)(vii)(IV), seeking approval to engage in the manufacture, use, sale, offer for sale, and/or importation of 75 mg and 150 mg dabigatran etexilate mesylate capsules (“Breckenridge’s ANDA products”) prior to the expiration of that patent.

16. On or about February 5, 2015, Breckenridge sent a letter (“Breckenridge’s Notice Letter”) to BIPKG and Boehringer Ingelheim Corp. in which Breckenridge represented that it had filed an ANDA for Breckenridge’s ANDA products, including the certification with respect to the '380 patent, and that it sought approval of its ANDA prior to the expiration of that patent.

17. Breckenridge’s Notice Letter did not provide complete and effective notice under 21 U.S.C. § 355(j)(2)(B)(iii) because Breckenridge has not served notice to BIPI.

18. This action was commenced within 45 days of the receipt of Breckenridge’s Notice Letter.

19. Because Breckenridge seeks approval of its ANDA to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of a drug claimed in the '380 patent, and a drug the use of which is claimed in the '380 patent, before its expiration, Breckenridge has infringed the '380 patent pursuant to 35 U.S.C. § 271(e)(2)(A).

20. Plaintiffs are entitled to a declaration that, if Breckenridge commercially manufactures, uses, sells, offers to sell, and/or imports any of Breckenridge's ANDA products, or induces or contributes to any such conduct, it would further infringe the '380 patent pursuant to 35 U.S.C. § 271(a), (b), and/or (c).

21. The commercial manufacture, use, sale, offer to sell, and/or importation of Breckenridge's ANDA products, if approved by the FDA, prior to the expiration of the '380 patent, for use in accordance with its proposed labeling would infringe and/or induce and/or contribute to the infringement of the '380 patent. Boehringer is entitled to relief provided by 35 U.S.C. § 271(e)(4), including an Order of this Court that the effective date of the approval of Breckenridge's ANDA No. 207922 be a date that is not earlier than the expiration date of the '380 patent, or any later expiration of exclusivity for the '380 patent to which Boehringer is or may become entitled.

22. Upon information and belief, Breckenridge was aware of the existence of the '380 patent, and was aware that the filing of its ANDA and certification with respect to the '380 patent constituted an act of infringement of that patent.

23. Plaintiffs will be irreparably harmed by Breckenridge's infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

STATEMENT REGARDING PRIOR-FILED SUIT

24. Boehringer previously filed, on March 5, 2015, an action in the District of New Jersey seeking to enjoin Breckenridge from infringing the '380 patent. That action has been assigned Civil Action No. 3:15-cv-01662-MLC-TJB ("the D.N.J. Action"). The D.N.J. Action is assigned to Judge Mary L. Cooper.

25. In the D.N.J. Action, Boehringer alleged that the District Court for the District of New Jersey has personal jurisdiction over Breckenridge with regard to Boehringer's claim of patent infringement.

26. Judicial economy would be promoted, and Boehringer's choice of forum respected, if the claim related to Boehringer's action for infringement of the '380 patent is addressed by Judge Cooper in the District of New Jersey.

27. Pursuant to 21 U.S.C. § 355(j)(5)(B)(iii), a patent owner has 45 days from receipt of an ANDA Notice Letter to file suit in order to perfect its statutory right to a stay of FDA approval of an ANDA pending resolution of litigation regarding the submission of such ANDA. Boehringer filed this action as a further protective measure with regard to this statutory right. Boehringer expects that personal jurisdiction will be maintained in the District of New Jersey and that the action will proceed in that forum. In that circumstance, this action would be unnecessary and will be promptly and voluntarily dismissed without prejudice in favor of continued prosecution of the D.N.J. Action, transferred to the District of New Jersey for consolidation with the D.N.J. Action, or subject to such other non-substantive disposition that would ensure maintenance of Boehringer's rights pursuant to 21 U.S.C. § 355(j)(5)(B)(iii).

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request the following relief:

A. A Judgment be entered that Defendant Breckenridge has infringed the '380 patent by submitting Breckenridge's ANDA No. 207922;


B. A Judgment be entered that this case is exceptional, and that Plaintiffs are entitled to their reasonable attorneys' fees pursuant to 35 U.S.C. § 285;

C. A permanent injunction be issued, pursuant to 35 U.S.C. § 271(e)(4)(B), restraining and enjoining Defendant Breckenridge, and its officers, agents, attorneys, and employees, and those acting in privity or concert with them, from engaging in the commercial manufacture, use, offer to sell, or sale within the United States, or importation into the United States, of the drugs or methods of administering drugs claimed in the '380 patent, including any exclusivities or extensions;

D. An Order be issued pursuant to 35 U.S.C. § 271(e)(4)(A) that the effective date of any approval of Breckenridge's ANDA No. 207922 be a date that is not earlier than the expiration date of the '380 patent, or any later expiration of exclusivity of the '380 patent to which Plaintiffs are or may become entitled; and

E. Such other and further relief as the Court may deem just and proper.

Dated: March 20, 2015

By: 

Jephtha F. Barbour
Florida Bar No.: 0347000
jbarbour@marksgray.com
Edward L. Birk
Florida Bar No.: 068462
ebirk@marksgray.com
MARKS GRAY, P.A.
Post Office Box 447
Jacksonville, FL 32201
Telephone: (904) 398-0900
Facsimile: (904) 399-8440

OF COUNSEL:

Bruce M. Wexler
Joseph M. O'Malley, Jr.
Eric W. Dittmann
Isaac S. Ashkenazi
Leonard A. Monfredo
PAUL HASTINGS LLP
75 East 55th Street
New York, NY 10022
Telephone: (212) 318-6000
Facsimile: (212) 230-7644

Attorneys for Plaintiffs
Boehringer Ingelheim Pharma GmbH & Co. KG,
Boehringer Ingelheim International GmbH, and
Boehringer Ingelheim Pharmaceuticals, Inc.